Proteinuria. Chronic kidney disease (CKD)
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will take empagliflozin 10 mg, manufactured by Actover Pharmaceutical Company, once a day for 3 months, along with RAAS and immunosuppressive
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: The age range is 18 to 75 years Urinary protein excretion of more than 500 mg/L eGFR=30 ml/min/1.7 m2 Patients with stage 1-3 chronic kidney disease Have taken ACEi and ARBs within 4 weeks prior to the start of the study
Exclusion criteria
Exclusion criteria: Diagnosis of type 1 or type 2 diabetes Cancer Any medication, surgery, or medical condition that significantly impairs absorption, distribution, metabolism, or excretion of drugs, such as a history of active inflammatory bowel disease within the past 6 months, major gastrointestinal surgery such as gastrectomy, gastroenterostomy, or bowel resection, gastrointestinal ulcer, gastrointestinal or rectal bleeding within the past 6 months, pancreatic injury or pancreatitis Liver disease ALT or AST values ??greater than 3×ULN on laboratory tests History of hepatic encephalopathy History of esophageal varices or portocaval shunt Evidence of urinary tract obstruction History of allergy or contraindication to empagliflozin Pregnancy or lactation Albuminuria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in 24-hour urine.;Urine creatinine. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in 24-hour urine.;24-hour urine volume. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in 24-hour urine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular function rate (GFR). Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in 24-hour urine.;Blood creatinine. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in blood.;Lipid profile. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in blood.;Fasting blood sugar. Timepoint: Before and 3 months after receiving the drug. Method of measurement: Measurement in blood. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Asgharpour
Babol University of Medical Sciences
Outcome results
None listed